Candel's High-Stakes Gamble on a Viral Therapy for Advanced Lung Cancer

NEEDHAM, Mass. – June 30, 2026 – In the high-stakes world of biotech, where fortunes are made and lost on clinical data, Candel Therapeutics (Nasdaq: CADL) just placed a massive bet. The company announced the initiation of a global pivotal Phase 3 trial, dubbed AURORA, for its lead viral immunotherapy candidate, aglatimagene besadenovec (CAN-2409). The target: patients with the most common form of lung cancer whose disease has relentlessly progressed despite the best tools in the modern oncology arsenal. This isn't just another trial; it's a defining moment for Candel and a potential paradigm shift for a patient population facing a grim prognosis.

The Story Behind the Numbers: A Glimmer of Hope

The decision to launch a costly, multi-year global trial hinges on what Candel describes as “encouraging” results from its earlier Phase 2 study. In this case, “encouraging” is an understatement. For patients with advanced non-squamous non-small cell lung cancer (NSCLC) whose tumors grew despite treatment with powerful immune checkpoint inhibitors (ICIs), the data is compelling. In this specific group—the very population the AURORA trial will enroll—median overall survival reached an impressive 25.4 months.

To understand the significance of that number, one must look at the current standard of care. For these patients, the next step is typically docetaxel, a decades-old chemotherapy that offers a bleak median survival of just 9.8 to 11.8 months. Candel’s Phase 2 data suggests CAN-2409 could more than double that lifespan. Furthermore, the data showed a remarkable long-term survival tail, with 50% of per-protocol patients alive beyond 24 months. This is the kind of data that justifies a high-stakes gamble.

“Patients whose lung cancer progresses despite immune checkpoint inhibitor therapy have limited treatment options, and outcomes with standard chemotherapy remain poor,” said Dr. Roy Herbst, a co-Principal Investigator of AURORA and a leading oncologist at Yale Cancer Center. “The survival results observed with aglatimagene in the phase 2 trial are particularly encouraging and support advancing the program into the pivotal phase 3 AURORA trial.”

The AURORA trial will randomize patients to receive either CAN-2409 in combination with continued pembrolizumab or the standard-of-care docetaxel. The primary endpoint is the gold standard in oncology: overall survival. It’s a straightforward, high-bar comparison that, if successful, could reshape treatment guidelines.

A Trojan Horse for Cancer

Behind these clinical numbers is a fascinating biological story. CAN-2409 is not a typical drug; it's a feat of bioengineering. The therapy is an “off-the-shelf” adenovirus—a common cold virus that has been rendered replication-defective and repurposed as a cancer-fighting agent. Injected directly into a tumor, the virus delivers a gene for an enzyme called herpes simplex virus thymidine kinase (HSV-tk).

This sets up a two-pronged attack. First, patients are given valacyclovir, a common antiviral pill. The HSV-tk enzyme converts the valacyclovir into a potent toxin that kills dividing cancer cells, causing them to burst in a process known as immunogenic cell death. This releases a flood of tumor-specific antigens into the bloodstream. Second, the adenovirus shell itself acts as a powerful adjuvant, ringing the alarm bells of the immune system and drawing inflammatory cells to the tumor site. The result is an in-situ, or “in-place,” personalized vaccine, training the patient’s own immune system to recognize and attack not only the injected tumor but also distant metastases.

“Our data suggest that aglatimagene may offer a novel approach by inducing an individualized, systemic anti-tumor immune response in patients who have very limited therapeutic options,” stated Paul Peter Tak, President and CEO of Candel. This approach aims to turn immunologically “cold” tumors, which are invisible to the immune system, into “hot” tumors that are ripe for attack—a critical strategy for overcoming resistance to ICIs.

The Financial Engineering of a Biotech Bet

Launching a global Phase 3 trial across 150 sites is a monumental financial undertaking for a clinical-stage company. Candel’s management, however, has been methodically assembling a war chest to fund this ambition. As of the latest quarter, the company reported nearly $195 million in cash, bolstered by a $100 million public offering in February 2026. This provides a cash runway projected to last into the first quarter of 2028, a crucial window for generating pivotal data.

Beyond equity financing, Candel has employed creative, non-dilutive strategies. A $130 million term loan facility provides access to capital upon hitting key milestones, and a clever $100 million royalty funding agreement, contingent on a future FDA approval for CAN-2409 in prostate cancer, de-risks its balance sheet. This financial architecture demonstrates a clear strategy to see the AURORA trial through to completion without being forced back to the capital markets from a position of weakness.

To manage the immense operational complexity, Candel has enlisted Parexel International, a top-tier global clinical research organization (CRO). This move signals to investors that the company is serious about execution, offloading the logistical burden of a global trial to a seasoned partner with a deep network and extensive oncology experience. It’s a classic de-risking maneuver that shores up the operational side of this ambitious clinical bet.

While the financial position appears solid, the cash burn is significant, with an operating cash flow of nearly -$48 million over the last twelve months. The stakes are clear: the success of Candel's advanced programs, particularly AURORA, is paramount. If the Phase 3 trial replicates the success of Phase 2, the return on this investment could be immense, given the significant unmet need in an NSCLC market worth billions. If it fails, the path forward becomes considerably more challenging. This is the story behind the numbers that will define Candel Therapeutics for years to come.